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INTRODUCTION 
 
TUBERCULOSIS 
 
 
Tuberculosis is a common and an infectious disease which is caused by the organisms 
"Mycobacterium tuberculosis" (M. tuberculosis) .[1] Tuberculosis (TB) is the second major 
cause of death due to an infectious disease in adults worldwide with nine million new cases 
and close to 1.8 million deaths annually . TB is caused by Mycobacterium tuberculosis, an 
airborne pathogen transmitted among humans which infects macrophages in the lungs.[2] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1
[3]
 :Mycobacterium tuberculosis 
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BACKGROUND 
  
TB was first discovered by Robert Koch in 1882. Robert Koch received the 
Nobel Prize in physiology or medicine for this discovery in 1905; The Bacterium is 
also known as "Koch's Bacillus".
[6]
 Tuberculosis is the second deadliest disease (first 
HIV/AIDS). In 2015, there were an estimated 10.4 million new (incident) TB cases 
worldwide, of which 5.9 million (56%) were among men, 3.5 million (34%) among 
women and 1.0 million (10%) among children. In 2006, WHO launched the new stop 
TB strategy. The core of this strategy is DOTS (directly observed treatment 
schedule).The strategy is to be implemented over 10 years, as described in the global 
plan to stop TB 2006-2015.
[4] 
 
 
The strategy is to be implemented over 10 years, as described in the global plan to 
stop TB 2006-2015.
[4] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2
[5]
 :Epidemiology of Mycobacterium tuberculosis 
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HISTORY 
  
The timeline in the history of tuberculosis is depicted below.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure3
[7]
 : History of TB 
 
 
 
MYCOBACTERIA 
 
.
 
 
Mycobacterium tuberculosis and seven very closely related mycobacterium 
species (M.bovis, M.africanum, M.microti, M.caprae, M.pinnipedii, M. Canetti and 
M. mungi) are together known as M.tuberculosis complex.
[9] 
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 SCIENTIFIC CLASSIFICATION 
[9] 
 
Kingdom : Bacteria. 
 
Phylum : Actinobacteria. 
 
Class : Actinobacteria. 
 
Order : Actinomycetales. 
 
Suborder : Corynebacterineae. 
 
Family : Mycobacteriaceae. 
 
Genus : Mycobacterium. 
 
Species : Mycobacterium tuberculosis. 
 
Synonym : Tubercle bacillus Koch 1882. 
 
 
           Mycobacterium Tuberculosis is the rod-shaped, spore forming aerobic 
bacterium.
[8]
Mycobacterium tuberculosis has an unusual, waxy coating on its cell 
surface (primarily due to the presence of mycolic acid), which makes the cell 
impervious to gram staining. 
 
 
CELL WALL STRUCTURE 
 
The cell wall structure of Mycobacterium tuberculosis deserves special 
attention because it is unique among prokaryotes, and it is major determinant of 
virulence for the bacterium.
[10]
 Mycobacterium Tuberculosis has a tough cell wall 
that prevents passage of nutrients into and excreted from the cell, therefore giving it 
the characteristic of slow growth rate
[11]
 .The cell wall complex contains 
peptidoglycan, but otherwise it is composed of complex lipids. The lipid fraction of 
MTB’s cell wall consist of three major components, mycolic acids, cord factor, and 
waxD.
[10] 
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The cell wall contains three classes of Mycolic acids: Alpha, keto, and 
methoxymycolates.
[11]
Mycolic acids are unique alpha branched lipids found in cell 
walls of mycobacterium and corynebacterium. The cell wall also contains lipid 
complexes including acyl glycolipids and sulfolipids. Beneath the cell wall there are 
layer of arabinogalacton and peptidoglycan that lie just above the plasma membrane.
 
 
The Cordfactoris toxic to mammalian cells and is also an inhibitor of 
polymorphonuclear leukocytes(PMN) migration.Freund's adjuvant is a solution 
of antigen emulsified in mineral oil and used as an immunopotentiator . The complete 
form, Freund's Complete Adjuvant is composed of inactivated and 
dried mycobacteria , whereas the incomplete form  lacks the mycobacterial 
components Wax D in the cell envelopes the major component of Freund’s 
completeadjuant(CFA).[10] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                        Figure 4
[12]
 :Mycobacterium tuberculosis cell wall structure 
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    GENOME 
 
Mycobacterium Tuberculosis genome encodes about 190 transcriptional 
regulators, including  sigma factors, two–component system and more than 140 
transcription regulators. Several regulators have been found to respond to 
environmental distress, such as extreme cold or heat, iron starvation, and oxidative 
stress.
[13] 
 
 
Mycobacterium Tuberculosis has circular chromosomes of about 4,200,000 
long nucleotide. The genome was studied generally using the strain Mycobacterium 
Tuberculosis H37RV.The genome has about 4000 genes. Genes that code for lipid 
metabolism are very important part of the bacterial genome and 8% of the genome is 
involved in its activity.
[14] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5
[15]
: Genome of Mycobacterium tuberculosis 
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MODE OF TRANSMISSION 
 
TB is usually spread through cough, sneeze, speak, sing, or spit, they expel 
infectious aerosol droplets 0.5 to 5.0µm in diameter. A single sneeze can release up to 
40,000 droplets. They transmit the disease, since the infectious dose of tuberculosis is 
very small. 
[6]
 
 
PATHO PHYSIOLOGY 
 
 
Mycobacterium tuberculosis is classified as acid- fast gram- positive bacteria 
due to their lack of an outer cell membrane. 
[10]
 It divides every 15-20 hours. Which 
is extremely slow compared to other bacteria, it is a small bacilli that can withstand 
weak disinfectants and can survive in a dry state for weeks.
[13] 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6
[16 ]
 : Pathophysiology of Mycobacterium tuberculosis 
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  DRUG -RESISTANT TB 
 
Drug resistant TB disease can develop in two different ways called primary and 
secondary resistance. Primary resistance occur in person who are initially exposed to and 
infected with resistant organism. Secondary resistance or acquired resistance 
develops during TB therapy either because the patient was treated with an inadequate 
regimen or did not take the prescribed regimen appropriately or because of other 
conditions such as drug mal absorption or drug-drug interactions that led to low serum 
levels. 
 
MDR TB is caused by organism resistant to both isoniazid and rifampicin 
which are the most effective anti Tb drugs. 
 
XDR TB is a relatively rare type of drug resistant TB, which is resistant to 
both isoniazid and rifampicin, plus any other fluoroquinolone and at least one of three 
injectable second line (i.e. amikacin, kanamycin, or capreomycin). 
[14] 
 
 
Need for new anti-TB drugs 
 
 To improve the treatment of MDR-TB.[15]

 To improve current treatment by shortening the total duration of the treatment.

 The recent rise in TB cases and especially the increase of drug resistant 
mycobacteria indicate an urgent need to develop new anti-TB drugs.

 There is a need to design new drugs that are more active against slowly 
growing and non growing persistent bacilli.

 Discovery of compound that would reduce both the length of treatment and 
the frequency of drug administration.
[16]

 To provide more effective treatment for latent tuberculosis infection.

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 New drug to improve current that would reduce both the total length of 
treatment and the frequency of drug administration.
 
 
 
 
 
 
ENZYME PROFILE:   
ENZYME NAME :  ENOYL-ACP REDUCTASE
[17] 
CLASSIFICATION :  OXIDO REDUCTASE 
POLYMER : 1 
TYPE : Protein 
CHAINS : A, B 
ORGANISM : Mycobacterium tuberculosis 
PROTEOME : Chromosome 
FUNCTIONAL CATEGORY : Type II fatty acid biosynthesis pathway 
 
 
InhA, the enoyl-ACP reductase in Mycobacterium tuberculosis is an attractive 
target for the development of novel drugs against tuberculosis, a disease that kills 
more than two million people each year. 
 
InhA is the target of the current first line drug isoniazid for the treatment of 
tuberculosis infections. Compounds that directly target InhA and do not require 
activation by the mycobacterial catalase-peroxidase Kat G are promising candidates 
for treating infections caused by isoniazid-resistant strains. 
 
However, these compounds are rapid reversible inhibitors of the enzyme, and 
based on the knowledge that long drug target residence times are an important factor 
for in vivo drug activity, which set out to generate a slow onset inhibitor of InhA 
using structure-based drug design. 2-(o-Tolyloxy)-5-hexylphenol (PT70) is a slow, 
tight binding inhibitor of InhA with a K (1) value of 22 pm. 
[18] 
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Crystal structure of the ternary complex between InhA, NAD(+), and PT70 
reveals the molecular details of enzyme-inhibitor recognition and supports the 
 
hypothesis that slow onset inhibition is coupled to ordering of an active site loop, 
which leads to the closure of the substrate-binding pocket. 
InhA (enoyl-[acyl-carrier-protein] reductase), involved in mycolic acid 
synthesis is a target of front-line anti-tubercular drugs, such as isoniazid and 
ethionamide.
[19] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                               Figure 7
[20]
: Crystal structure of Inh A (enoyl ACP) R 
 
 BASIC NUCLEUS INTRODUCTION 
 
Heterocyclic structures always are a part in the field of research and     
development in organic chemistry. Millions of heterocyclic structures are found to 
exist having special properties and biological important. 
Benzimidazole could be a heterocyclic aromatic chemical compound. It's a 
crucial pharmacophore and privileged structure in medicative chemistry. It plays a 
awfully vital role with lots of helpful therapeutic activities such as: antiulcers, 
antihypertensives, analgesic,medication, antivirals, antifungals and anticancers 
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The review of the literature shows that the benzimidazole derivatives square 
measure effective compound and range of reviews on the market for organic 
chemistry and medical specialty studies conformed that their molecules square 
measure helpful against a good style of micro-organisms. Due to their importance. [21] 
Benzimidazole derivatives exhibit pharmacological activities such as 
antimicrobial, antiviral, anticancer, anti-inflammatory, analgesic, etc. The substituted 
benzimidazoles are summarized in this review to know about the chemistry as well as 
pharmacological activities. 
The benzo derivative of imidazole is refered to as benzimidazole . 
Although benzimidazole is the commonest name of the parent compound of the 
series, other names such as benzimidazole and 1,3-benzodiazole (1) are often used. 
 
N
H
N
 
 
                               Benzimidazole derivative are associated with various types of 
pharmacokinetic and pharmaco dynamic properties. Benzimidazole nucleus is one of 
the bioactive   heterocyclic compounds that exhibit a range of biological activities 
.Specifically, this nucleus is a constituent of vitamin B12 .The pharmacological activities 
of the benzimidazole containing moiety have been   well documented .Albendazole, 
Mebendazole and Thiabendazole are widely used as   anthelmintic drugs.[22] 
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DRUG DISCOVERY 
 
 
The process of drug discovery is very complex and requires interdisciplinary 
effort to design effective and commercially feasible drugs. Earlier drug discovery has 
been a trial and error process. The process of drug development has evolved with 
time. New understanding of the quantitative relationship between structure and 
biological activity ushered the beginning of computer –aided drug design with the 
help of computers, a new era has begun in drug discovery. The development cost will 
be cut by almost third. The development times are reduced.
[23] 
 
LEAD AND LEAD OPTIMIZATION 
 
 
              A lead is defined as a compound, usually a small organic molecule that 
demonstrates desired biological activity on a validated molecular target. Lead 
optimization is technique of refining 3D structures of drug molecules and promoting 
the binding of drug to protein active sites. In this technique modification of a 
structureof the drug molecules is done by docking every specific structure of a drug 
compound in active site of protein and calculating the extent of the interaction.
[24]
 
Optimization aids in the several modification of newer molecules in order to improve 
the physico-chemical properties and biological activity for a given set of compounds 
in the library.
[23]
 Further structural modification improves the affinity, reactivity 
towards target and enhances stability during metabolism. 
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TYPES OF DRUG DESIGN 
 
 
Advances in computation techniques and hardware have facilitated the 
application of in-silico methods in the discovery process drug design can be 
categorized as two types 
 Structure based drug design
 Ligand based drug design
 
 
Structure based drug design: 
 
 
SBDD is the approach where the structural information of the drug target is 
exploited for the development of inhibitors receptor structure(s) is a prerequisite for 
this method. Most commonly the structure of the receptor is determined by 
experimental techniques such as X-ray crystallography or NMR. If the structure of the 
protein drug target is not available, protein structure can be predicted by 
computational methods threading and homology modelling. 
 
Ligand based drug design: 
 
 
           It is also called indirect drug design. Ligand based drug design is an approach 
used in the absence of the receptor 3D information and it relies on knowledge of 
molecules to the biological target of interest. 3D quantitative structure 
activityrelationship (3D QSAR) and pharmacophore modelling are the most important 
and widely used tools in the ligand based drug design. They can provide protective 
models suitable for lead identification and optimization.
[25] 
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COMPUTER AIDED DRUG DESIGN 
 
 
Computer aided drug design use as computational chemistry to discover, 
enhance or study drugs and related biologically active molecules. Molecular 
mechanics or molecular dynamics are most often used to predict the confirmation of 
the small molecule and to model conformational changes in the biological target but 
may occur when the small molecules binds to it. 
 
Molecular mechanics methods may also be used to provide semi quantitative 
prediction of the binding affinity also knowledge based scoring function may be used 
to provide binding affinity estimates.
[26] 
 
Drug design with the help of computers may be used at any of the following 
stages of drug discovery 
 
 Hit identification using virtual screening (structure or ligand based-
baseddesign)

 Hit-to-lead optimization of affinity and selectivity (structure based 
design,QSAR, etc)

 Lead optimization, optimization of other pharmaceutical properties 
whilemaintaining affinity.
 
In order to overcome the insufficient prediction of binding affinity calculated 
by resent scoring functions, the protein-ligand interaction and compound 3D structure 
are used to analysis 
[27] 
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AIM AND OBJECTIVE 
 
 
 
AIM: 
To develop the novel and potent anti-tubercular agents 
 
OBJECTIVE: 
The plan of work includes: 
 Design of InhA (enoyl-ACP reductase) inhibitors by docking studies using Argus 
lab 4.0® software.
 Insilico Drug likeness prediction.
 Insilico Toxicity Assessment.
 Laboratory synthesis of those compounds with top Docking Scores.
 Characterization of the synthesized compounds by
 Infrared Spectroscopy.
 H1 Nuclear Magnetic Resonance Spectroscopy.
 Melting point.
 GC-Mass Spectroscopy.
 LC-Mass Spectroscopy.
 In-vitro anti -tubercular activity of synthesized compounds (MABA). 
AIM AND OBJECTIVE  
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PLAN OF WORK 
 
      The present study will be carried out based on the flow chart given below: 
     
                             Inh-A(ENOYL ACP-REDUCTASE)TARGET FROM 
                                     MEDICAL CHEMISTRY JOURNALS 
   
                                                                             PHARMACOPHORE 
                 
    AUTODOCK                                                                                                KNOWLEDGE 
          ARGUS                          FRAGMENT AND                                           BASED DRUG 
         PDB:2h9i                               DOCKING                                                    DESIGN       
 
                                               CHEMICAL AND              
                                             TOXICITY FILTERS                                 DRUG 
                                                                                                   ,              LIKENSS 
   
   20 HITS OF DIFFERENT                                                                    
             ANALOGUE                                                                                              PRIORITY                                                                       
                                                                                                                       GIVEN  BASED ON 
                                                                                                                              SYNTHETIC  
                                                                 SYNTHESIS                                      FEASIBILITY 
                                                                                                                          AND CHEMICAL 
                                                                                                                            AVAILABILITY 
 
                                       PURIFIED BY RECRYSTALLISATION AND  
                                            COLUMN CHROMATOGRAPHY 
 
     
                                CHARACTERIZATION  BY USING IR,NMR,GC-MS,LC,MS            
 
     BIOLOGICAL EVALUATION ANTI-TUBERCULAR ACTIVITY MABA METHOD 
 
                                         ACUTE TOXICITY BY USING MICE 
 
 
                                                                   CYTOTOXITY 
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REVIEW OF LITERATURE 
 
In order to know the current status regarding the advances in TB the literature 
pertaining to the disease, design, synthesis, characterisation and biological evaluation 
were reviewed. 
Literature review on Tuberculosis research : 
1. Robert Koch., (2008) has outlined the History of Tuberculosis[28] 
2. Frieden TR, GR et al.,(2003) has shown that “Impact of national consultants 
on successful expansion of effective tuberculosis control in India.
[29] 
3. Williams, B.G et al., (2010) studied the “The Population Dynamics and 
Control of Tuberculosis.
[30] 
4. Leimane  V,et  al.,  (2005)  described  the “Clinical  outcome  of  
individualized treatment of multidrug-resistant tuberculosis 
[31] 
5. Balabanova Y,et al., (2006) made a report about “The Directly Observed 
Therapy Short-Course (DOTS) strategy”[32] 
6. Keane, J, et al.,(1997) explained that “Mycobacterium Tuberculosis promotes 
Human alveolar macrophage apoptosis, Infection and immunity.”[33] 
7. Lonnroth K, et al.,(2006) has studied the Productive engagement of private 
providers in tuberculosis control. 
[34] 
8. Duncan k, et al., (2004) developed, “Prospects for New Anti-Tubercular 
drugs.
[35] 
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9. Pierpalo de colombai., et al.,(2007) has described  The Global Plan to Stop 
TB.[36]
 
10. Ruohonen RP, et al., (2002) performed the “Implementation of the DOTS 
strategy for tuberculosis.
[37] 
11. Bumburidi E, et al., (2006) explained the Disease Control and Prevention 
(CDC)in this article, “Progress toward tuberculosis control and determinants 
of treatment outcomes.
[38] 
12. M, Coker RJ et al., (2007) studied the Reform of tuberculosis control and 
DOTS within public health systems.
[39] 
Literature review for drug design : 
13. Alfred burger, et al.,(1984) Textbook of guide to chemical basis of drug 
design(John Wiley& Sons).
[44]
 
14. Edward.C.Olson,et al.,(1979)Textbook of Computer assisted Drug 
Design(American Chemical Society).
[45]
 
15. Wilson & Giswold’s et al.,(2011) Text book of Organic, Medicinal and 
Pharmaceutical chemistry
[46]
 
16. Romono T. Kroemeret et al..,(2003)“An introduction into ligand–receptor 
docking”.[47] 
17. Lipinski CA et al., (2001) developed an experimental and computational 
approach to estimate solubility and permeability in drug discovery and 
development settings.
[48]
 
18. Madsen et al., (2002) Textbook of Drug Design and Discovery.[49] 
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  The Review of Literature related to the desired chemical entities: 
19. Anu Kajal et al. reported Schiff base a versatile pharmacophore. Schiff bases 
are condensation product of primary amine with carbonyl compound gaining 
important day by day in present scenario. Schiff bases are compound carrying 
imine or azo methane. (-C=N-) functional group and are found to be versatile 
pharmacophore for design and development of various bio active lead 
compounds
. [50] 
20. Ruchi Agarwal et al. Schiff base complexes derived from 
thiosemicarbazones, synthesis characterisation and the biological activity. The 
Schiff base anisasldehyde thiosemicarbazone,3,4 dimethoxy benzaldehyde 
thiosemicarbazone, thiophene 2 aldehyde thiosemicarbazone
.[51] 
21. Angelo De Fathima et al. Schiff base: A short reviews of the 
antimicrobialactivities Schiff base are aldehyde or ketone like compounds in 
which the carbonyl group is replaced and imine or azomethane group. The 
widely used for industrial purposes and biological activities
.[52] 
22. S.K. Ghosh et al. Synthesis of Schiff base in aqueous medium a green 
alternative approaches with effective mass yield and high reaction rates. Schiff 
base constitute a class of pharmaceutical and medicinally important 
molecules. Various Schiff bases by stirring 1,2 diamino benzene with various 
aromatic aldehydes in water as solvent
.[53] 
23. Ina Boltz et al. Novel Schiff bases derived from 5 amino barbituric acid: 
synthesis and a solid state structure for this purpose 1,3 and dimethyl and 
1butyl 5amino butyric acid are condensed with p-nitro and p-N,N dimethyl 
amino cinnamaldehyde respectively
.[54] 
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24. Shelar Mahendra Devidas et al. Novel One–pot synthesis of schiff 
basecompounds derived from different diamine & aromatic aldehydes 
catalyzaed by P2O5/Sio2 Under free solvent condition at room temperature. A 
potential method for one-pot synthesis of schiff base compounds derived from 
different aldehyde and diamine by using catalyst P2O5/Sio2. 
[55] 
 
25. Hamid Latif Siddiqui et al. synthesis of spectroscopic studies of new 
Schiffbases. Five novel Schiff bases have been prepared from o-formyl 
phenoxyacetic acid and a ries of amino thiazoles to form a number of 
potentially biologically active compounds
.[56] 
 
26. 1.2-benzisothi- azole hydrazides as well as their cyclic and acyclic 1.2-
benzisothiazole parent hydrazides.
[57] 
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27. Schiff bases by reacting 5-chloro-licylaldehyde and primary amines. The 
compounds were assayed for antibacterial (Bacillus subtilis, Esh- erichia coli, 
Pseudomonas fluorescence and Staphylo- coccus aureus)
. [58]
 
 
 
 
 
 
 
28. Aromatic Schiff bases and 2,3-di- ia and co-workers have reported the 
synthesis two neryl-1,3-thiazolidin-4-one (Scheme 11) derivatives have been 
prepared and tested for anti-inflammatory and antinociceptive activities. 
[59] 
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Literature review for benzimidazole : 
29. Kumar et al reported a series of novel and functionalized benzimidazole 
derivatives  shown anti-diabetic activity against DPP-IV and PTP-IB.[60] 
 
 
 
 
30. Kazimierczuk et al reported Synthesis of substituted 2-polyfluroalkyl and 
2-nitrobenzyl sufanyl benzimiazole  Compounds were evaluated for their 
activity against mycobacterium strains. [61] 
 
N
H
N
SR2R
R1=Cl,Br
R2=methy nitro benzene  
 
 
 
N 
N 
S 
H 
3 
C 
R 
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31. Sondhi etal. reported Synthesis of pyrimido [1,6-a] benzimidazole 
derivatives [62] 
 
N
H
N+
NH
NH
R1
R2  
 
32. Chimrri et al reported this synthesis of novel 1H-pyrrolo (1,2-
a)benzimidazole-1-one derivative. [63] 
 
 
 
 
 
 
 
 
 
N 
H 
N 
R 
2 
R 
3 
R 
1 
O 
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33.  Alagoz et al reported Synthesis of some 6-flouro-5-substituted 
benzimidazole.[64] 
 
34. Leonardo et alreportedSynthesis and anti-inflammatory activity of phenyl 
benzimidazole..[65] 
 
 
 
35. Gellis et al reported some new benzimidazole-4,7-diones substituted at 2-
position  were synthesized.[66] 
 
 
 
N 
N 
C H 
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Review of Literature related to the evaluation of anti tubercular activity by 
MABA 
36. Scott G Franzblau. et al. studied MIC determination by MABA. A colorimetric, 
Microplate Based Alamar Blue Assay (MABA) method was used to determine 
the MICs of Isoniazid, Rifampin, Streptomycin and Etambutol for 34 peruvian 
Mycobacterium tuberculosis isolates and the H37Rv strain by using bacterial 
suspensions prepared directly from media. The MABA is a simple, rapid, low 
cost, appropriate technology which does not require extensive instrumentation 
and which makes use of a nontoxic, temperature stable reagent. 
[67] 
37. Sephra N Rampresad. et al. studied the various applications of Alamar Blue 
asan indicator. Alamar Blue is a redox indicator that is used to evaluate 
metabolic function and cellular health. The Alamar Blue Bioassay is being 
utilized to access cell viability and cytotoxicity in a range of biological and 
environmental system and in a number of cell types including bacteria, yeast, 
fungi, and protozoa. 
[68] 
38. Jose de Jesus Alba-Romero et al. applied the Alamar Blue Assay to 
determinethe susceptibility to anti-tuberculosis pharmaceuticals. 
[69] 
Literature review on target enzyme Inh A (enoyl ACP reductase) Inhibitors: 
39. Luckner, S.R et al., (2010) reported that Inh A, the enoyl-ACP reductase 
inMycobacterium tuberculosis is an attractive target for the development of 
novel drugs against tuberculosis.
[70]
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40. Argyrou, A. et al., (2007) developed new insight into the mechanism of 
action ofand resistance to isoniazid: interaction of Mycobacterium 
tuberculosis enoyl-ACP reductase with INH-NADP.
[71]
 
41. Dias, M.V. et al., (2007) studied the crystallographic studies on the binding 
ofisonicotinyl-NAD adduct to wild-type and isoniazid resistant 2-trans-enoyl-
ACP (CoA) reductase from Mycobacterium tuberculosis.
[72]
 
42. Vilcheze, C.et al., (2006) developed the transfer of a point mutation in 
Mycobacterium tuberculosis.
[73]
 
43. Argyrou, A. et al., (2006) has shown the dihydrofolate reductase 
frommycobacterium tuberculosis is inhibited by the acyclic 4R isomer of 
INH-NADP a derivative of the prodrug isoniazid.
[74]
 
From the literature review the following points are concluded 
 TB is the deadliest disease across the world wide which has to be treated.
 Inh A (enoyl ACP- Reductase) is the most attractive target enzyme to treat 
Mycobacterium tuberculosis.
 It is clear that Benzimidazole scaffold has a tremendous activity against the 
Mycobacterium tuberculosis from the literature review.
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MATERIALS AND METHODS 
 
The Project is to be carried out in the following phases. 
 
 Drug design by using Argus lab 4.0.
 Synthesis of the designed molecules.
 Characterization of the synthesized molecules.
 Biological evaluation of the synthesized molecule
 
DRUG DESIGN PROCESS

 
A) DOCKING STUDY 
 
The synthesized compounds are docked against the target protein by using 
Argus lab® software. The flow chart of the docking study is presented below 
 
 
 
 
 
Figure 8
[76]
 : Molecular docking and Drug design 
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B) MOLECULAR PROPERTY PREDICTION: 
The designed and docked molecules were screened insilico using  
MOLINSPIRATION
®
  Software to evaluate the drug likeness. Molinspirsation
®
  is 
used to calculate the important properties such as log P, polar surface area, number of 
hydrogen bond donor and acceptors. 
Molecular toxicity property prediction includes. 
 Drug likeness prediction
 clogP predicition.
 Solubility prediction.
 Molecular weight.
 Drug likeness score
 
DRUG LIKENESS: 
 
Druglikeness may be defined as a complex balance of various molecular 
properties and structure features which determine whether particular molecule is 
similar to the known drugs. These properties, mainly hydrophobicity, electronic 
distribution, hydrogen bonding characteristics, molecule size and flexibility and of 
course presence of various pharmacophoric features influence the behavior of 
molecule in a living organism, including bioavailability, transport properties, affinity 
to proteins, reactivity, toxicity, metabolic stability and many others. Simple count 
criteria (like limits for molecular weight, logP, or number of hydrogen bond donors or 
acceptors) have also relatively limited applicability and are useful only to discard 
obvious non-drugs 
(93) 
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A model compound for the lipophilic cellular membrane is octanol (a 
lipophilic hydrocarbon), so the logarithm of the octanol/water partition coefficient, 
known as LogP, is used to predict the solubility of a potential oral drug. This 
coefficient can beexperimentally measured or predicted computationally, in which 
case it is sometimes called "cLogP 
 
clogP PREDICTION: 
 
The logP value of a compound, which is the logarithm of its partition 
coefficient between n-octanol and water log (coctanol/cwater), is a well established 
measure of the compound's hydrophilicity. Low hydrophilicities and therefore high 
logP values cause poor absorption or permeation. clogP value must not be greater 
than 5.0 for permeability. 
 
SOLUBILITY PREDICTION: 
 
Aqueous solubility is one of the most important physico-chemical properties 
in modern drug discovery. It has impact on ADME-related properties like drug 
uptake, distribution and even oral bioavailability. Solubility can also be a relevant 
descriptor for property-based computational screening methods in the drug discovery 
process.[77] 
 
MOLECULAR WEIGHT: 
 
Optimizing compounds for high activity on a biological target almost often 
goes along with increased molecular weights. However, compounds with higher 
weights are less likely to be absorbed and therefore to ever reach the place of action. 
Thus, trying to keep molecular weights as low as possible should be the desire of 
every drug forger. 
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LIPINSKI’S RULE OF FIVE 
[78] 
 
The rule was formulated by Christopher A.Lipinski in 1997. Lipinski's ruleof 
five also known as the Pfizer's rule of five or simply the Rule of five (RO5) is to 
evaluate druglinkness or determine if a chemical compound with a certain 
pharmacological or biological activity has properties that would make it a likely 
orally active drug in humans. The rule is important to keep in mind during drug 
discovery when a pharmacologically active lead structure is optimized step-wise to 
increase the activity and selectivity of the compound as well as to ensure drug-like 
physicochemical properties are maintained as described by Lipinski's rule. 
Candidate drugs that conform to the RO5 tend to have lower attrition rates 
during clinical trials and hence have an increased chance of reaching the market. 
Lipinski's rule states that, in general, an orally active drug has no more than 
one violation of the following criteria: 
 
 
Figure 9
[43]
 : Lipinski rule of five 
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VARIANTS 
In an attempt to improve the predictions of druglikeness, the rules have 
spawned many extensions,  
1. Partition coefficient log P in −0.4 to +5.6 range 
2. Molar refractivity from 40 to 130 
3. Molecular weight from 180 to 500 
4. Number of atoms from 20 to 70 (includes H-bond donors [e.g. OHs 
and NHs] and H-bond acceptors [e.g. Ns and Os]) 
Also the 500 molecular weight cutoff has been questioned. Polar surface area 
and the number of rotatable bonds has been found to better discriminate between 
compounds that are orally active and those that are not for a large data set of 
compounds in the rat. 
In particular, compounds which meet only the two criteria of: 
1. 10 or fewer rotatable bonds and 
2. Polar surface area no greater than 140 A2 are predicted to have good 
oral bioavailability. 
C) TOXICITY RISK ASSESSMENT: 
 
All the docked molecules can be subjected to the toxicity risk assessment by 
using OSIRIS® program, which is available online. The OSIRIS® property Explorer 
is an integral part of Actelion's in house substance registration system. Prediction 
results are color coded in which the red colour shows high risks with undesired effects 
like mutagenicity or a poor intestinal absorption and green colour indicates drug-
conform behaviour.
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On drawing a structure the toxicity risk predictor will start looking for 
potential toxicity risks as long as the currently drawn structure is a valid chemical 
entity. Toxicity risk alerts are an indication that the drawn structure may be harmful 
concerning the risk category specified 
[79] 
 
ACUTE ORAL TOXICITY STUDY: 
Acute oral toxicity study (Limit Test) was designed as per the OECD 
guidelines(423). 
Principles and purpose 
The main purpose of acute toxicity is to evaluate the degree of toxicity in a 
quantitative and qualitative manner. 
Experimental Animals 
Six healthy adult Albino mice were weighing between 20-25g were selected 
for the study. For all the six animals food, but not water was withheld overnight prior 
to dosing. 
Selection of dose levels and administration of dose: 
Being synthetic molecules, the mortality was unlikely at the highest starting 
dose level (2000mg/kg/b.w). Hence a limit test one dose levels of 2000mg/kg/b.w was 
conducted in all animals as per the OECD guidelines (423). 
Procedure: 
Animals are observed individually after dosing at least once during the first 30 
minutes, periodically during the first 24 hours, with special attention given during the 
first 4 hours, and daily thereafter, for a total of 14 days, except where they need to be 
removed from the study and humanely killed for animal welfare reasons or are found 
dead. However, the duration of observation should not be fixed rigidly. It should be 
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determined by the toxic reactions, time of onset and length of recovery period, and 
may thus be extended when considered necessary. The times at which signs of 
toxicity appear and disappear are important, especially if there is a tendency for toxic 
signs to be delayed. All observations are systematically recorded with individual 
records being maintained for each animal. 
COMPUTER-AIDED DRUG DESIGN 
[80] 
 
Computer-aided drug design uses computational chemistry to discover, 
enhance, or study drugs and related biologically active molecules. Molecular 
mechanics or molecular dynamics are most often used to predict the conformation of 
the small molecule and to model conformational changes in the biological target that 
may occur when the small molecule binds to it. Molecular mechanics methods may 
also be used to provide semi quantitative prediction of the binding affinity. Also, 
knowledge-based scoring function may be used to provide binding affinity estimates. 
Drug design with the help of computers may be used at any of the following stages of 
drug discovery: 
 hit identification using virtual screening (structure or ligand-based design)

 hit-to-lead optimization of affinity and selectivity (structure-based design, 
QSAR, etc.)

 lead optimization: optimization of other pharmacokinetic properties while 
maintaining affinity. In order to overcome the insufficient prediction of 
binding affinity calculated by recent scoring functions, the protein-ligand 
interaction and a compound‟s 3D structure information are used for analysis.

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TYPES OF DRUG DESIGN:
[81] 
Drug design is carried out by either of the two methods. SBDD is opted when 
the structure of the target protein is known i.e. established by a PDB ID. 
 Ligand based drug design.
 Structure based drug design.
STEPS INVOLVED IN DOCKING 
[40],[41],[42] 
Docking can be carried out using a number of software available for the 
purpose. GLIDE
®
 (Schrodinger) AUTODOCK
®
 and ARGUS LAB
®
 are a few of 
them. The steps involved in general are 
1. Protein preparation. 
2. Selection of active site (Q-Site finder). 
3. Ligand Preparation. 
4. Docking Procedure. 
5. Visualization / Interpretation of Docking. 
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1. PROTEIN PREPARATION 
 
The various operations of the protein preparation are tabulated below. 
  
 
 
 
Step: 1 
 Enter protein (pdb) ID in the protein data bank. (2X22)
 Go to download files and select pdb as text file.
 Save the download pdb (text file) to the desktop.
Step: 2 
 Open Argus lab file – Open Import pdb file from the desktop.
 3D Structure of the protein will appear in the workspace of Argus 
lab.
 Left side of the screen shows molecular tree view.
 Open pdb – Open „residues‟  – „Open misc‟ 
 From  „Misc‟   delete  the  inhibitor  and  hetero  residues  [Note: 
Do  not delete Co-factor] Open water press shift, select all water 
molecules and delete.
 Add hydrogen atoms.
 Calculation on the toolbar – energy by UFF method start. Save the 
prepared protein as *.agi file format in the desktop
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2. Q-SITE FINDER 
 
 
 
Step: 1 
 Open Q-Site finder through online.
 Upload / Import the PDB format of the Protein.
 Find all the active site and make a list out of the common amino acid 
residues.
Step: 2 
 Open residues – open Amino acids. 
 Press control and select the amino acid which listed from the Q-Site 
finder. 
 Make sure that all amino acid residues listed are selected. 
 Right click on the mouse – make a group from the selected residues 
 Give name Binding site – Ok 
 
 
3. LIGAND PREPARATION 
 
The various operations of the ligand preparation are tabulated below 
 Draw the structure from Chemsketch and save as MDL Mol format.
 Import the ligand into workspace of Argus lab.
 Clean Geometry – Clean Hybridisation.
 Select the ligand, Right click on the mouse
 Make a group from the residues give name ligand – Ok.
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4. DOCKING PROCEDURE 
 
 
The procedure for docking are tabulated below  


 Select the set up a Dock Ligand calculation from the toolbar.
 Argus Dock as the Docking Engine.
 Dock was selected as calculation type.
 Flexible for the scoring function.
 Calculation size.
 Start docking.
 Save the Docked protein Ligand complex as Brookhaven 
pdb files (*.pdb)



5. VISUALIZATION / INTERPRETATION OF DOCKING 
 
The visualization of docking is tabulated below  
 
 
 
 Molegro Molecular viewer helps in analyzing the energies and 
interaction of the binding. 
 “View Secondary” helps to view the Structure. 
 “View” – Hydrogen bond interaction. 
 “Ligand map” – Interaction overlay. 
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SYNTHETIC METHODOLOGY 
 
The designed and docked compounds are synthesized by the following scheme 
which presented below. 
 
 
 
SYNTHESIS 
The compounds with top docking score were selected for synthesis as per the 
scheme below. The necessary chemicals of laboratory grade for the synthesis were 
procured from Sigma Aldrich and synthesis was carried out. 
SCHEME 
[75]
 
 
 
 
 
 
 
 
 
 
 
 
PROCEDURE 
A mixture of 0.01 mole 2-amino benzimidazole and 0.01 mole of aromatic 
aldehyde  is dissolved in dimethyl formamide and refluxed for 6-7 hr. The reaction 
mixture is slowly poured over crushed ice. The solid mass thus separated is filtered, 
dried, and purified by recrystallization from methanol. 
 
 
 
 
N
N
O
R
NH2
O
N
N
R
N
OH2SO4
DMF
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REACTANT PROFILE 
 
 2-Aminobenzimidazole 
 
 
 
 
 
 
Molecular formula : C7H7N3 
 
  Molecular weight : 133.154g/mol  
 
  Description : white powder. 
 
  Melting point : 435
o
F 
 
 
 Dimethylformamide 
 
 
N O
H
 
 
 
 
Molecular formula : C3H7NO 
  
Molecular weight : 73.10g/mol 
 
Description : Colourless liquid. 
 
Melting point : 61
o
C 
 
Boiling point : 154°C 
 
 
 
 
 
 
N
H
N
NH2
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 Sulphuric acid 
 
 
 
 
H2SO4  
 
 
 
 
Molecular formula : H2SO4 
 
Molecular weight : 98.07g/mol 
 
Description : Colourless liquid. 
 
Melting point : 10
o
C 
 
Boiling point : 337°C 
 
 
 
 P-Chlorobenzaldehyde 
 
 
Cl
H O
 
 
 
Molecular formula: C7H5CLN3 
 
Molecular weight: 140.56g/mol. 
 
Description: White crystalline solid 
 
Melting point: 117°C 
 
Boiling point: 415°F 
 
MATERIALS AND METHODS 
 
Department of Pharmaceutical Chemistry, COP, MMC, Chennai - 03 Page 41 
 
 3-Nitro Benzaldehyde 
 
 
 
Molecular formula: C7H5NO3 
 
Molecular weight: 151.12g/mol. 
 
Description: Pale yellow powder 
 
Melting point: 43°C 
 
Boiling point: 152°C 
 
 
 
 P-Hydroxy Benzaldehyde 
 
   
  
 
Molecular formula : C7H6O2 
 
Molecular weight : 122.12g/mol. 
 
Description : Light brown. 
 
Melting point : 112-116°C 
 
Boiling point : 196°C 
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 Salicylaldehyde 
 
 
OH
H
O
 
 
 
Molecular formula : C7H6O2 
 
Molecular weight : 122.12g/mol. 
 
Description : Colourless liquid. 
 
Melting point : 7°C 
 
Boiling point : 197°C 
 
 
 
 Anisaldehyde 
 
 
H
O
O  
 
 
   Molecular formula: C8H8O2 
 
   Molecular weight: 136.15g/mol. 
 
   Description: SlightlyYellow  liquid. 
 
   Melting point: 1°C 
 
   Boiling point: 248°C 
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CHARACTERIZATION 
 
The compound is checked for purity by TLC method and sharp melting 
point. 
 
PHYSICAL EVALUATION: 
 
Physical properties of the synthesized compounds are evaluated, such as 
 Colour
 Nature
 Solubility
 Molecular weight
 Molecular formula
 Melting point
 Boiling point

Further the synthesized compounds are to be characterized by the following 
Spectroscopic and Spectometric methods. 
 
IR SPECTROMETRY 
Infrared (IR) spectrometry is one of the most common spectroscopic 
techniques used by organic chemists for detection of functional compounds and 
mixtures and for compound comparison. The spectrum obtained in minutes using a 
few mg of the compound which can also be recovered. IR spectroscopy is an 
important and popular tool for structural elucidation and compound identification. 
Infrared spectrum shows per cent transmittance versus frequency expressed as wave 
numbers 
[82] 
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1. 3540-3300 cm-1 N-H Stretching Vibration 
2. 3670-3230 cm-1 O-H Stretching Vibration 
3. 1690-1630 cm-1 C=N Stretching Vibration 
4. 2975-2840 cm-1 C-H Aliphatic Stretching Vibration 
NMR SPECTROSCOPY 
 Nuclear magnetic resonance (NMR) spectroscopy is the important analytical 
technique available for organic chemist. It involves the interaction of the 
electromagnetic radiation and the hydrogen of the nucleus when placed in an external 
static magnetic field. NMR spectra will provide detailed information about a 
molecule's structure and will prove what the compound really is. NMR is a non-
destructive technique. The NMR spectra were recorded on 300 MHz BRUKER 
Advance III NMR spectrometer. DMSO was used as a solvent 
[83] 
1. Aromatic and hetero aromatic compounds 6-8.5 δ 
2. Alcoholic hydroxyl protons 1-5.5 δ 
3. Aldehyde protons 9-10 δ 
 
HYPENATED TECHNIQUE: 
 
 
GC-MS: 
 
Gas chromatography-mass spectrometry is a hyphenated technique, consisting 
of two analytical procedures in sequence, namely a gas chromatography (GC) 
separation followed by Mass spectroscopy (MS) detection. The purpose of GC step is 
to separate multiple compounds in a sample so that they reach the MS detector one at 
a time.[85] 
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LC-MS 
 
LC-MS is a hyphenated technique, combining the separation power of HPLC, 
 
 with the detection power of mass spectroscopy 
[84] 
 
 
 
 
 
 
 
 
BIOLOGICAL EVALUATION 
Anti-tubercular Activity 
There are various high throughput assays available for screening of new 
chemical entities against tuberculosis. They are: 
 Microplate Alamar Blue Assay
 BACTEC Assay
 Luciferous Reporter Phage assay
 Resazurin Micro plate Assay(REMA)
 Broth Micro Dilution Assay
 Middle brook (7H 9,7H 10,7H 11) Agar Dilution Assay.
 Nitrate Reductase Assay
MICROPLATE ALAMAR BLUE ASSAY (MABA) 
[86] 
 The anti- mycobacterial activities of the synthesized compounds were 
determined by MABA method. The organism used in the studies 
M.tuberculosis H37Rv.
 Alamar blue dye is used as an indicator for the determination of viable cells.
  
Liquid 
chromatography 
 
Ionization 
 
Mass analyzer 
 
Detector / Data 
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Principle: 
MABA is an indirect colorimetric method for determining the MICs of TB 
drugs for strains of mycobacterium tuberculosis. In this assay, the redox indicator 
Alamar blue monitors the reducing environment of the living cells. It turns from blue 
to pink in the presence of mycobacterium growth. 
Procedure: 
1) The anti-mycobacterial activity of the compounds are to be assessed against 
M. tuberculosis using microplate Alamar blue assay (MABA). 
2) This methodology is non- toxic, uses a thermally stable reagent and shows 
good correlation with proportional and BACTEC radiometric method. 
3) Briefly, 200 ml of sterile deionized water is added to all outer perimeter wells 
of sterile 96 wells plate to minimize evaporation of medium in the test wells 
during incubation. 
4) The 96 wells plate received 100µl of the Middle brook 7H9 broth and serial 
dilution of compounds are placed directly on plate. 
5) The final drug concentrations tested is made up to 100 to 0.2µg/ml. 
6) Plates are covered and sealed with Para film and incubated at 37oC for five 
days. 
7) After this time, 25µl of freshly prepared 1:1 mixture of Alamar Blue reagent 
and 10% Tween 80 was added to the plate and incubated for 24hrs. 
8) A blue colour in the well is interpreted as no bacterial growth, and pink colour 
was scored as growth. 
 The MIC is defined as lowest drug concentration which prevents the colour 
change from blue to pink 
[87]  
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RESULTS AND DISCUSSION 
 
 
RESULTS OF DRUG DESIGN 
PREDICTION FOR ACTIVITY 
(INSILICO DRUG DESIGN) 
   
More than 200 compounds were docked against the MTB enzyme Inh A 
(Enolyl Acyl Carrier Protein) (2h9i) by using Argus lab 4.0.1® software.The 
compounds with the best docking score and good interaction molecules were 
selected and screened. The  docking score and the view for different compound is 
presented below. 
 
Table 1: Docking Score And View Using Argus Lab 4.0® 
 
Compound 
Code 
Structure 
Docking 
Score 
Docking View 
RJ 
N
H
N
N
Cl
 
-7.83 
Kcal/mol 
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RK 
N
H
N
N
N O
O
 
-8.52 
Kcal/mol 
 
RM 
N
H
N
N
OH
 
-7.35 
Kcal/mol 
 
RN 
N
H
N
N
OH  
-7.54 
Kcal/mol 
 
RO 
N
H
N
N
O
CH3 
-7.64 
Kcal/mol 
 
 
 
  
RESULTS AND DISCUSSION 
 
Department of Pharmaceutical Chemistry, COP, MMC, Chennai - 03 Page 49 
 
Table 2 : 2h9i  Interaction With Ligand 
Compound 
Code 
Interaction with Aminoacid Hydrogen bond Interaction 
RJ 
  
RK 
  
RM 
  
RN 
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Compound 
Code 
Interaction with Aminoacid Hydrogen bond Interaction 
RO 
  
 
PREDICTION FOR TOXICITY 
(INSILICO) 
 
 OSIRIS® Property Explorer is the online software of Thomas Sander, Actelion 
Pharmaceuticals Ltd., Gewerbestrasse 16, and 4123 Allschwil, Switzerland. This applet 
predicts physico-chemical properties and detects potential toxicity risks for any drawn 
chemical structure in real time. The prediction result is indicated by color codes. For 
predicting properties of a chemical compound the structure was drawn and Property 
Explorer  starts calculating properties as soon as a chemical structure is valid. Properties with 
high risks of undesired effects like mutagenicity or a poor intestinal absorption are shown in 
red. Whereas green colour indicates the drug conform behaviour. 
TABLE 3 : PREDICTION OF TOXICITY USING OSIRIS® PROPERTY EXPLORER 
 
TOXICITY 
PARAMETERS 
COMPOUND CODE 
      RJ      RK     RM     RN    RO 
MUTAGENIC Nil Nil Nil       Nil      Nil 
TUMOROGENIC Nil        Nil Nil       Nil      Nil 
IRRITANT Nil Nil Nil       Nil      Nil 
REPRODUCTIVE 
EFFECT 
     Nil      Nil Nil     Nil     Nil 
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Snap shot of the results of insilico toxicity predictions is given below: 
 
Sample Code: RJ 
 
 
 
Sample Code: RK 
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Sample Code: RM 
 
 
 
Sample Code: RN 
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Sample Code: RO 
 
 
   None of the componds RJ,RK,RM,RN and RO exhibited any form of toxicity. 
. 
 
DRUG LIKENESS PREDICTION 
(INSILICO) 
 
The designed and docked molecules were screened insilico using 
Molinspirationcheminformatics
® 
to evaluate drug likeness. Molinspiration
®
is used 
to calculate important molecular properties such as log P, polar surface area, number 
of hydrogen bond donors and acceptors. 
 
Lipinski’s rule of five explains the ability of the chemical compound with 
certain pharmacological or biological activity to make it orally active drug. This rule 
describes the important pharmacokinetics properties like adsorption, distribution, 
metabolism and excretion (ADME). 
 
These drug likeness properties which were determined using molinspiration
®
 are 
presented here. 
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INSILICO SCREENING OF DRUG LIKENESS 
 
COMPOUND NAME: RJ 
 
 
 
COMPOUND NAME: RK 
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COMPOUND NAME: RM 
 
 
 
COMPOUND NAME: RN 
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COMPOUND NAME: RO 
 
 
 
 
SYNTHESIS 
 
The selected 5 compounds were synthesized and recrystallised. Then the synthesized 
compounds were evaluated for their purity through melting point determination and checking 
for the absence of parent functional groups and the presence of the newly formed functional 
group. TLC was performed on different solvent system of different polarities to ensure 
presense of single spot. 
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TABLE 4: RESULTS OF SYNTHETIC EFFORTS 
S.NO Compound 
code 
Molecular 
weight 
Percentage 
Yield 
Melting 
point 
1 RJ 255.70g/mole 80% 180°C 
2 RK 266.25 g/mole 75% 138°C 
3 RM 237.26 g/mole 85% 143°C 
4 RN 237.26 g/mole 70% 116°C 
5 RO 251.28 g/mole 70% 148°C 
 
The Rf value of the synthesized compounds varied from the Rf value of the reactants. 
Hence it is concluded that the reaction was completed.  
CHARACTERISATION 
The synthesized compounds were subjected to purification by recrystallization and 
TLC. The melting point of the synthesized compounds  founded. The characterization was 
carried out using sophisticated instruments like IR, NMR, and Mass spectrometry and 
characteristic properties through the aid of computer software. 
Infrared Absorption Spectroscopy: 
The IR spectrums of the synthesized compounds were inspected for presence of the new 
functional group and absence of the functional group which induced the changes in the 
chemical reaction. 
 The absorption band for RK  compound shows that the strong band at 1373 cm-1 and 
1365 cm-1 respectively indicating the presence of NO group. 
 For all the synthesized compounds showing the presence of NH stretching vibration 
between 3450- 3100cm-1, aromatic CH stretching vibration between 2880-2600 cm-1 
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H1 NMR Spectroscopy: 
Proton NMR spectroscopy help us to study the number of equivalent protons and 
their environment thereby we can ascertain the structure of molecule. The positions of the 
signals help us to know the nature of protons viz, aromatic, hetero aromatic, aliphatic, vinyl 
C-H groups. The H1 NMR spectral data of all the synthesized compounds are in conformity 
with the structure assigned. A singlet at 11.02-11.35 was observed for all compounds 
confirming the presence of N-H proton. All the compounds shows the multiplet and doublet 
signals for the presence of aromatic protons between (6.2-7.4) hetero aromatic protons 
between (7.2-7.8) δ ppm. 
Gas chromatography-Mass Spectrometry: 
GC is used to determine the purity of compounds based on additional peaks in the 
sample which are not present in the pure compound. The purpose of the GC step is to 
separate multiple compounds in a sample so that they reach the MS detector one at a 
time.The molecular ion peak of the spectrum showing the synthesized compounds were 
formed. 
The synthesized compounds are undergoing two types of cleavage namely  
 HOMOLYTIC CLEAVAGE 
 HETEROLYTIC CLEAVAGE 
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TABLE5:  MOLECULAR WEIGHT OF THE SYNTHESIZED COMPOUNDS 
 
 
NAME OF 
COMPOUNDS 
 
 
CALCULATED MASS 
 
 
ACTUAL MASS 
 
RJ 255.99 g/mole 255.70 g/mole 
RK 267.03g/mole 266.25 g/mole 
RM 237.36 g/mole 237.26 g/mole 
RN 237.99 g/mole 237.26 g/mole 
RO 252.04 g/mole 251.28 g/mole 
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PRODUCT PROFILE 
 
 
CODE: RJ 
IUPAC Name:N-(-1H-BENZIMIDAZOLE-2-YL)-1-(CHLOROPHNYL)METHANIMINE 
N
H
N
N
Cl
 
Molecular Formula: C14H10CLN3  
Formula Weight: 255.702g/mol 
Appearance: Yellow colour. 
Melting Point: 180oC  
Solubility: Chloroform, Methanol, Ethanol.  
Percentage Yield: 80%  
Composition:  C [65.76%], H[3.94%], CL[13.86%], N[16.43%] 
Molar Refractivity: 73.18±0.5 cm3 
Molar Volume: 195.9±7.0 cm3 
Parachor: 518.6±8.0 cm3 
Index of Refraction: 1.669±0.05 
Surface Tension: 49.1±7.0 dyne/cm  
Density: 1.30±0.1g/ cm3 
Polarizability: 29.01±0.5 10-24 cm3 
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IR SPECTRUM: RJ 
 
 
S.No Wave number (cm-1) Functional group 
1 
2 
3 
4 
 
743 
2684 
2877 
3317 
 
-C-CL Stretching 
-C=N Stretching 
-C-N Stretching 
-N-HStretching 
 
 
 
 
 
 
 
LC-MS SPECTRUM :RJ 
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H1 NMR SPECTRUM :RJ 
RESULTS AND DISCUSSION 
 
Department of Pharmaceutical Chemistry, COP, MMC, Chennai - 03 Page 63 
 
 
 
 
 
S.No 
 
δ VALUE 
(RJ) 
NATURE OF 
PEAK 
NUMBER OF 
PROTONS 
 
1 
 
2 
 
3 
 
4 
 
5 
 
δ7.3 
 
δ7.9-8.0 
 
δ8.3-8.6 
 
δ8.9 
  
δ10.2 
 
Doublet 
 
Doublet 
 
Multiplet 
 
Singlet 
 
Singlet 
 
2 Protons 
 
2 Protons 
 
4 Protons 
 
1 Protons 
 
1 Protons 
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CODE: RK 
 
IUPAC Name: N-(1H-BNZIMIDAZOLE-2-YL)-1-(3-NITROPHENYL)METHANIMINE 
 
 
N
H
N
N
N O
O
 
 
 
Molecular Formula: C14H10N4O2 
Formula Weight: 266.2548g/mol 
Appearance:yellowish orange.  
Melting Point: 138oC  
Solubility: Chloroform, Methanol, Ethanol.  
Percentage Yield: 75%  
Composition:  C [63.15%], H [3.79%], N [21.04%], O [12.02%] 
Molar Refractivity: 74.724±0.5 cm3 
Molar Volume: 191.9±7.0 cm3 
Parachor: 535.2±8.0 cm3 
Index of Refraction: 1.700±0.05 
Surface Tension: 60.4±7.0 dyne/cm  
Density: 1.38±0.1g/ cm3 
Polarizability: 29.43±0.5 10-24cm3 
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IR SPECTRUM: RK 
 
 
S.No Wave number (cm-1) Functional groups 
1 
2 
3 
4 
1510 
3317 
3078 
2746 
 
-NO2 Stretching(Aromatic) 
-N-H Stretching 
-C-H Stretching 
-C=N Stretching 
 
 
 
 
 
 
 
 
 
LC-MS SPECTRUM: RK 
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H1 NMR SPECTRUM :RK 
 
 
S.No 
 
δ VALUE 
(RK) 
NATURE OF 
PEAK 
NUMBER OF 
PROTONS 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
 
 
δ6.5 
 
δ6.9 
 
δ7.1-7.2 
 
δ7.4-7.7 
 
δ8.2 
 
δ9.5 
 
δ12.8 
 
Singlet 
 
Singlet 
 
Doublet 
 
Doublet 
 
Doublet 
 
Singlet 
 
Singlet 
 
 
 
1 Protons 
 
1 Protons 
 
2Protons 
 
2 Protons 
 
2 Protons 
 
1 Protons 
 
1 Protons 
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CODE: RM 
 
IUPAC Name: 3-[(E)-(1H-BENZIMIDAZOLE-2-YLIM INO)METHYL]PHENOL 
 
N
H
N
N
OH
 
Molecular Formula: C14H11N3O 
Formula Weight: 237.25g/mol 
Appearance: Red colour.  
Melting Point: 143oC  
Solubility:  Ethanol, Chloroform  
Percentage Yield: 85%  
Composition:  C [70.87%], H [4.67%], N [17.71%], O [6..74%] 
Molar Refractivity: 69.43±0.5cm3 
Molar Volume: 183.88.0cm3 
Parachor: 495.4±8.0cm3 
Index of Refraction: 1.679±0.05 
Surface Tension: 52.07±7.0 dyne/cm  
Density: 1.29±0.1g/cm3 
Polarizability: 27.52±0.5 10-24cm3 
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IR SPECTRUM :RM 
 
 
 
S.No Wave number (cm-1) Functional group 
1 
2 
3 
4 
 
2607 
2877 
3348 
3155 
 
-C=N Stretching 
-C-H Stretching 
-O-H Stretching  
-N-H Stretching 
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LC-MS SPECTRUM: RM 
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H1 NMR SPECTRUM :RM 
 
 
 
S.No 
 
δ VALUE 
(PPM) 
NATURE OF 
PEAK 
NUMBER OF 
PROTONS 
 
1 
 
2 
 
3 
 
4 
 
 
 
δ5.1 
 
δ6.-8.0 
 
δ9.4 
 
δ10.9 
 
 
 
Singlet 
 
Multiplet 
 
Singlet 
 
Singlet 
 
1 Protons 
 
7 Protons 
 
1 Proton 
 
1 Proton 
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CODE: RN 
 
IUPAC Name: 2-[(E)-(1H-BENZIMIDAZOL-2-YLIM INO )METHYL]PHENOL 
 
N
H
N
N
OH  
 
Molecular Formula: C14H11N3O 
Formula Weight: 237.256g/mol 
Appearance: Greenish yllow.  
Melting Point: 116oC 
Solubility: Chloroform, Methanol, Ethanol.  
Percentage Yield: 70%  
Composition:  C [70.8722%], H [4.67%], N [17.71%], O [6.74%] 
 Molar Refractivity: 69.43±0.5 cm3 
Molar Volume: 183.8±7.0 cm3 
Parachor: 495.4±8.0 cm3 
Index of Refraction: 1.679±0.05 
Surface Tension: 52.7±7.0 dyne/cm  
Density: 1.29±0.1g/ cm3 
Polarizability: 27.52±0.5 10-24cm3 
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IR SPECTRUM :RN 
 
 
S.No Wave Number (cm-1) Functional group 
1 
2 
3 
4 
3564 
3317 
2877 
2646 
 
-O-H Stretching 
-N-H Stretching 
-C-H Stretching 
-C=N Stretching 
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LC-MS SPECTRUM :RN 
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H1 NMR SPECTRUM :RN 
 
 
 
S.No 
 
δ VALUE 
(PPM) 
NATURE OF 
PEAK 
NUMBER OF 
PROTONS 
 
1 
 
2 
 
3 
 
4 
 
        5 
 
 
δ7.0 
 
δ7.2 
 
δ7.5 
 
δ7.6 
 
δ7.9 
 
Doublet 
 
Doublet 
 
Triplet 
 
Singlet 
 
Doublet 
 
 
 
2 Proton 
 
2 Protons 
 
3 Proton 
 
1 Proton 
 
2 Protons 
 
 
 
 
 
 
 
 
 
RESULTS AND DISCUSSION 
 
Department of Pharmaceutical Chemistry, COP, MMC, Chennai - 03 Page 76 
 
 
CODE: RO 
 
IUPAC Name: (E)-N-(1H-BENZIMIDAZOL-2-YL)-1-(4-
METHOXYPHNYL)METHANIMINE 
 
N
H
N
N
O
CH3
 
 
Molecular Formula: C15H13N3O 
Formula Weight: 251.28g/mol 
Appearance: buff colour.  
Melting Point: 148oC  
Solubility: Chloroform, Methanol, Ethanol.  
Percentage Yield: 70%  
Composition:  C [71.70%], H [5.21%], N [16.72%], O [6.37%]  
Molar Refractivity: 74.39±0.5 cm3 
Molar Volume: 208.3±7.0 cm3 
Parachor: 540.0±8.0 cm3 
Index of Refraction: 1.632±0.05 
Surface Tension: 45.1±7.0 dyne/cm  
Density: 1.20±0.1g/ cm3 
Polarizability: 29.49±0.5 10-24 cm3 
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IR SPECTRUM : RO 
 
 
 
S.No Wave Number (cm-1) Functional group 
1 
2 
3 
4 
 
2873 
3055 
2777 
3217 
 
-O-CH3 Stretching 
-C=H Stretching 
-C=N Stretching 
-N-H  Stretching 
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LC-MS SPECTRUM : RO 
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H1 NMR SPECTRUM : RO 
 
 
 
S.No 
 
δ VALUE 
(PPM) 
NATURE OF 
PEAK 
NUMBER OF 
PROTONS 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
 
δ4.5 
 
δ5.0 
 
δ5.5 
 
δ5.8 
 
δ6.0-6.2 
 
 
 
Singlet 
 
Singlet 
 
Singlet 
 
Triplet 
 
Multiplet 
 
 
 
1 Protons 
 
1 Protons 
 
3 Protons 
 
3 Protons 
 
5 Proton 
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BIOLOGICAL EVALUATION 
  
The anti-tubercular activities of the synthesized compounds were determined by 
MicroplateAlamar Blue Assay method (MABA). The organism used in the study is 
Mycobacterium tuberculosis H37Rv. All the synthesized compounds showed anti-
mycobacterial activity in varying degrees against the organism tested. The data pertaining to 
these observations are presented in the table[6] below. 
 
TABLE 6: ANTI-TB RESULTS 
 
 
SL. 
NO 
 
SAMPLES 
 
100 
μg/ml 
 
 
50μg/ml 
 
 
25 
μg/ml 
 
12.5 
μg/ml 
 
6.25 
μg/ml 
 
3.125 
μg/ml 
 
1.6 
μg/ml 
 
0.8 
μg/ml 
 
1. RJ S S S S S S R R 
2. RK S S S S S S S R 
3. RM S S S R R R R R 
4. RN S S S R R R R R 
5. RO S S S S S S S R 
 
NOTE: S - Sensitive    R - Resistant 
Strain used: M.tuberculosis(H37 RV strain): ATCC No- 27294.  
Here are the standard values for the Anti-Tb test which was performed.  
Pyrazinamide- 3.125μg/ml  
Streptomycin- 6.25μg/ml 
Ciprofloxacin-3.125μg/ml 
                         Compounds RK and RO were found to be more activity than the standard 
drugs.They are active at 1.6μg/ml.   
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                       RK which shows activity at 3.125μg/ml was found to be as active as 
Pyrazinamide and Ciprofloxacin. 
                          Compounds RM and RN were found to be less active than the standard drugs. 
 
SAMPLE DRUG PHOTOGRAPH 
 
 
 
STANDARD DRUG PHOTOGRAPH 
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ACUTE ORAL TOXICITY STUDY 
Compounds RJ and RK which was found to be the active were taken for 
active toxicity study and the animals were observed for behavioral signs of toxicity 
like motor activity, tremor etc., and no significant toxic signs were observed during 14 
days. The results of the acute toxicological studies revealed that the administration of 
2 molecules by oral route upto 2000mg/kg/b.w did not produce any mortality and it 
was tolerated. The results of the observation are tabulated in table[7] below. 
Table 7. Acute Oral Toxicity study  
S.No. PARAMETERS RESULTS 
1. Toxic signs Absent 
2. Pre-terminal deaths Nil 
3. Body weight No specific change 
4. Motor activity Normal 
5. Tremors Absent 
6. Convulsions Absent 
7. Straub reaction Absent 
8. Righting reflex Present 
9. Lacrimation and Salivation Normal 
10. Unusual vocalization Absent 
11. Sedation Absent 
12. Body temperature Normal 
13. Analgesia Absent 
14. Ptosis Absent 
15. Diarrhoea Absent 
16. Skin colour Normal 
17. Respiration Normal 
18. Scratching Absent 
19. Aggressiveness and restlessness Absent 
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CYTOTOXICITY EVALUATION: 
  Table 8. Cytotoxicity results 
Concentration 
(µg/ml) 
RJ RK 
500 98.14 96.96 
250 97.99 91.42 
125 92.51 49.09 
64.5 72.92 26.22 
31.25 40.99 9.99 
IC50 from 
Prism 
37.63 111.2 
 
 These two compounds, RJ and RK shows decreased IC50 Values of 37.63   
and 111.2 µg/ml. 
The IC50 for Rifampicin is 113 µg/ml on vero cell line. The reported values 
of the compounds were compared with standard drugs. 
Therefore as compared to Rifampicin the synthesized compounds were 
found to be more cytotoxic  
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                                                             DISCUSSION 
1. The synthesized compounds have best docking score against targeted enzymes 
and were synthesized in an appropriate manner, and the purity of the compounds 
were justified by single spot on TLC and sharp melting point. 
2. Among 5 compounds, 2 of them were obtained at 98% and it was confirmed by 
LC-MS analysis (single peak) and molecular weight obtained at ± 1 variation 
(M+1 or   M-1 peak). The presence of corresponding functional groups was 
obtained from FT-IR spectrum by obtaining specific absorption band in the 
spectra. The types of protons and no of protons were confirmed by H1 NMR 
Spectra. 
3. All the 5 compounds were obeyed Lipinski Rule of 5 and Rule of Seven for     
Druglikeness by Molinspiration®. 
4. Osiris Property Explorer® showed that all the 5 compounds  are non toxic. 
5. The biological evaluation MABA of the compounds is denoted that the specific 
organism was sensitive at  25,1.6, 3.125 mcg/ml and showed better activity 
compared to standard drugs.  
6. Acute toxicity study revealed that the selected compounds was relatively non 
toxic upto 2000mg/kg/b.w, indirectly pronouncing safety profile of the 
compounds. 
7. The IC50 values of synthesized compounds was observed by Cytotoxicity study 
against Vero ( African Green Monkey kidney cells) cell line.  
8.From the  literature review the benzimidazole nucleus shows antitubercular 
activity. According to the results of my work NH amino on 3rd  position and N 
nitrogen in benzimidazole nucleus. 
8. Cl on 4th  position of the nucleus having good antitubercular activity and NO2  on 
3rd position of the second compound  nucleus had given good activity. 
10.3rd and 6th position of OH group dcreased activity than other three compounds. 
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SUMMARY 
 Enoyl acyl carrier protein reductase is a vital enzyme present in the cell wall of 
Mycobacterium tuberculosis. 
 A database of 200 molecules with high prospects of inhibiting the target Enoyl acyl 
carrier protein reductase  were carefully chosen by making changes to the known hit 
molecules, here the Benzimidazole nucleus waschosen. 
 The designed molecules were docked against the target chosen using AutoDock 4®. 
 Five molecules with good docking score [lower binding energy] and interactions were 
shortlisted for synthesis. Reaction conditions wereoptimized. 
 The selected molecules were subjected to toxicity prediction assessment by OSIRIS® 
property explorer developed by Acetilon Pharmaceuticals limited which is available 
online. The results are color coded as green color which predicts the drug likeness and 
possibly betteractivity. 
 The molecules were labelled as RJ, RK, RM, RN, RO and were synthesized with 
satisfactoryyield. 
 The purity of the synthesized compounds was ensured by repeated recrystallization. 
Further the compounds were evaluated by TLC and Melting pointdetermination. 
 The characterization of the synthesized compounds was done using Infra-red, Nuclear 
Magnetic Resonance [H1 NMR] and Mass spectrometric methods [LC-MS]. 
 All the Synthesized compounds exhibited molecular ion peak (M+) of varying 
intensities. 
 The final pure compounds were screened for Anti-mycobacterial activity by in vitro 
method called Micro plate Alamar Blue Assay[MABA]. 
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 The synthesized compounds showed sensitivity [Minimum inhibitory concentration] 
at 1.6mcg/ml. The standard drugs Pyrazinamide, Ciprofloxacin and Streptomycin 
exhibited anti-mycobacterial activity at 3.125 mcg/ml, 3.125 mcg/ml and 6.25mcg/ml 
concentrations respectively. This indicates that the synthesized compounds are as 
Potent as the standarddrugs. 
 The selected compounds showed IC50 Values of 37.63,111.2μg/ml respectively for 
RJ,RK. 
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CONCLUSION 
 It is concluded that the synthesized compounds might effectively inhibit the chosen 
target Enoyl acyl carrier protein reductase which is essential for the Mycobacterial 
tuberculosis. Further structural modifications of the synthesized compounds will aid in the 
development of potential molecule against the pathogen. 
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